{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019170","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.578572+00:00","generated_at":"2026-06-15T09:11:57.607733+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corbus Q1 net loss widens to $17.7M; in-licenses CRB-701 Nectin-4 ADC","bullets":["Net loss of $17.7M ($4.24 per share) vs $9.4M ($2.26) in Q1 2022.","Operating expenses rose $8.8M to $17.3M, driven by $7.5M CRB-701 license upfront.","Cash and investments $44.2M; runway expected through Q2 2024.","In-licensed CRB-701 (Nectin-4 ADC) from CSPC; Phase 1 in China, US trial by mid-2024.","CRB-601 IND on track for H2 2023; Dr. Yong Ben appointed to board March 1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019170","json":"https://secwatch.observer/filing/0000950170-23-019170.json","markdown":"https://secwatch.observer/filing/0000950170-23-019170.md","text":"https://secwatch.observer/filing/0000950170-23-019170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023019170/0000950170-23-019170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023019170/crbp-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:11:57.607733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ded4d1c359702288a38e94b635076a12367536d7","claim":"Corbus Pharmaceuticals Holdings, Inc. reported the three months ended March 31, 2023 results: net income a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, EPS a net loss per diluted share of $4.24.","evidence_excerpt":"The Company reported a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023019170/0000950170-23-019170-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24"},{"label":"EPS","value":"a net loss per diluted share of $4.24"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}